UnknownPhase 3ketamine
Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting
Sponsored by University of Washington
NCT ID
NCT02303847
Target Enrollment
32 participants
Start Date
2014-11
Est. Completion
2015-06
About This Study
This project is a pilot study to evaluate the analgesic and opioid-sparing effects of ketamine in an ultra-low dose oral formulation as a novel intervention for treatment of chronic non-cancer pain in opioid-tolerant patients in the primary care outpatient setting.
Conditions Studied
Interventions
- •Ketamine
Eligibility
Age:18 Years - N/A
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: * Age 18 years or older * Routine use of an opioid medication for non-cancer pain for more than six months * A current average daily dose of greater than or equal to 20 mg morphine or equivalent * Current prescription of an as-needed opioid suitable for downward titration during the study period * Ability to provide informed consent Ability to adhere to the study protocol Exclusion Criteria: * Uncontrolled hypertension, cardiac arrhythmia or other known cardiac disease, * elevated intracranial pressure, * severe glaucoma, * schizophrenia, * diagnosed substance use disorder, or * other unstable medical or psychiatric illness or pregnancy.
Study Locations (1)
Pioneer Family Practice
Lacey, Washington, United States